Trials / Terminated
TerminatedNCT03639766
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon, a Double-Blind Randomized Placebo-Controlled Trial
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- University of Central Florida · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.
Detailed description
This prospective double-blind randomized control trial seeks to compare a single formulation of BoNT, aboboutlinum toxin A (Dysport), to a placebo saline group, studying the effect of BoNT on Raynaud's symptoms among a more diverse population to provide insight into the patients most likely to benefit from BoNT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AbobotulinumtoxinA | AbobotulinumtoxinA reconstituted in non-bacteriostatic saline solution |
| OTHER | Saline solution | Non-bacteriostatic saline solution |
Timeline
- Start date
- 2018-08-31
- Primary completion
- 2020-01-31
- Completion
- 2020-01-31
- First posted
- 2018-08-21
- Last updated
- 2021-06-30
- Results posted
- 2021-06-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03639766. Inclusion in this directory is not an endorsement.